

Letters to the Editor

Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug

^{1,3}Mohamed Nabil Ibrahim and ²Abdo Abdellah Elfiky

¹Department of Clinical Laboratory Sciences, Jouf University, Saudi Arabia

²Department of Biophysics, Cairo University, Egypt

³Department of Microbiology, Ain Shams University, Egypt

Article history

Received: 02-03-2021

Revised: 30-04-2021

Accepted: 03-05-2021

Corresponding Author:

Mohamed Nabil Ibrahim
Department of Clinical
Laboratory Sciences, Jouf
University, Saudi Arabia
E-mail: mnabil@ju.edu.sa

Abstract: The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.

Keywords: Sofosbuvir-COVID-19-RNA Polymerase-Therapy

Dear Editor

Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 149 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +3.15 M died. Nucleotide Inhibitors (NI) have promising results in terms of their efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) (Gane *et al.*, 2013). Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent.

The Ebola virus NI, Remdesivir, was authorized for emergency use by the Food and Drugs Administration (FDA) against COVID-19 in May 2020. Various studies reported the *in silico* effectiveness of other nucleotide inhibitors currently in the market against SARS-CoV-2 (Elfiky, 2020a). The study utilized a structure of SARS-CoV-2 RdRp for small molecule screening. Also, protein dynamics were simulated for 100 ns. Sofosbuvir is currently used for HCV treatment since the FDA approved it in 2013 (Gane *et al.*, 2013). The safety profile of Sofosbuvir was tested over millions of people worldwide and different companies are manufacturing it at affordable prices in low-income countries like India and Egypt (Omar *et al.*, 2018; Elsharkawy *et al.*, 2017; Shah *et al.*, 2017). Sofosbuvir is able to bind to RdRp of SARS-CoV-2 with comparable binding energies compared to Remdesivir (Fig. 1) (Elfiky, 2020b; Jácome *et al.*, 2020; Elfiky *et al.*, 2021).

The dynamics were simulated using the NAMD software utilizing the CHARMM36 force field (Huang and MacKerell, 2013; Phillips *et al.*, 2005). A water box (TIP3P model) is added to the system with added NaCl salt concentration adjusted to be in the physiological value (154 mM) (Mark and Nilsson, 2001). After dynamics, Maestro is utilized to cluster the trajectories to be tested using the docking protocol (Schrödinger, 2017-1). AutoDock Vina is used in the docking study, while AutoDock tools and PyMOL are used to prepare the docking files and to analyze the data (Rauf *et al.*, 2015; Trott and Olson, 2010). The docking grid was adjusted to cover the active site aspartates (D760 and D761) using the flexible ligand and flexible active site protocol.

As reflected in Fig. 1, the Sofosbuvir is successfully fitted inside the nucleotide channel by forming contacts with the channel-lining residues (blue sticks in the lower enlarged panel of Fig. 1). Six H-bonds (with S549, R555(2), R624(2) and N691), four hydrophobic contact (with Y455, K551, R553 and K621) and two salt bridges (with R555 and R624) are established.

The binding affinity of Sofosbuvir (-7.4±0.3 kcal/mol) is very close to that for Remdesivir (-7.3±0.1 kcal/mol) against SARS-CoV-2 RdRp. This affinity is persistent during 25 ns MDS run on the formed complex. In previous studies on a model for SARS-CoV-2 RdRp built before the first structure was released, Sofosbuvir shows similar results regarding the binding affinity and the binding mode (Elfiky, 2020a-c; Jácome *et al.*, 2020). Sofosbuvir proved its safety and anti-HCV activity during the last eight years and may be a potential SARS-CoV-2 inhibitor.




Fig. 1: Sofosbuvir at SARS-CoV-2 RdRp active site pocket. The docking pose of sofosbuvir (orange sticks) in the active site of SARS-CoV-2 RdRp (conformation at 28.1 ns) (surface) depicted by PyMOL software. The interactions are shown in blue, dashed gray and dashed-yellow lines for H-bonding, hydrophobic contacts and salt bridges. The SARS-CoV-2 RdRp interacting residues are shown in blue stick in the lower enlarged panel and labeled by its one-letter code

Sofosbuvir shows a prominent binding affinity to the RdRp and tightly interacting with the binding site; hence, supposed to be the right candidate against COVID-19. It could be used to inhibit SARS-CoV-2 RdRp, which yet to be confirmed through experimental binding assays. Currently, we are working on modified sofosbuvir compounds to optimize the drug for SARS-CoV-2 RdRp further. Conclusively, *in vitro* binding studies and *in vivo* studies needed to confirm our suggestion that Sofosbuvir could be a therapeutic option against SARS-CoV-2 by targeting its polymerase.

Acknowledgement

Computational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University, is acknowledged.

Ethics

This article is original and contains unpublished material. The corresponding author confirms that all of the other authors have read and approved the manuscript and no ethical issues involved.

Authors Contributions

Mohamed Nabil: Funding, revisions and final form of the manuscript.

Abdo A Elfiky: Drafting the manuscript and figure Generation.

Reference

- Elfiky, A. A. (2020a). Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life Sciences*, 248, 117477. <https://doi.org/10.1016/j.lfs.2020.117477>
- Elfiky, A. A. (2020b). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sciences*, 253, 117592. <https://doi.org/10.1016/j.lfs.2020.117592>
- Elfiky, A. A. (2020c). SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An *in silico* perspective. *Journal of Biomolecular Structure and Dynamics*, 1-9. <https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1761882>
- Elfiky, A. A., Azzam, E. B., & Shafaa, M. W. (2021). The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase *in silico*. *Molecular Diversity*, 1-11. <https://doi.org/10.1007/s11030-020-10178-z>
- Elsharkawy, A., Fouad, R., El Akel, W., El Raziky, M., Hassany, M., Shiha, G., ... & Esmat, G. (2017). Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. *Alimentary Pharmacology & Therapeutics*, 45(5), 681-687.

- Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., ... & Berrey, M. M. (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *New England Journal of Medicine*, 368(1), 34-44. <https://www.nejm.org/doi/full/10.1056/nejmoa1208953>
- Huang, J., & MacKerell, Jr, A. D. (2013). CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. *Journal of Computational Chemistry*, 34(25), 2135-2145. <https://doi.org/10.1002/jcc.23354>
- Jácome, R., Campillo-Balderas, J. A., de León, S. P., Becerra, A., & Lazcano, A. (2020). Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. *Scientific Reports*, 10(1), 1-5. <https://www.nature.com/articles/s41598-020-66440-9>
- Mark, P., & Nilsson, L. (2001). Structure and dynamics of the TIP3P, SPC and SPC/E water models at 298 K. *The Journal of Physical Chemistry A*, 105(43), 9954-9960. <https://pubs.acs.org/doi/abs/10.1021/jp003020w>
- Omar, H., El Akel, W., Elbaz, T., El Kassas, M., Elsaheed, K., El Shazly, H., ... & El Shazly, Y. (2018). Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. *Alimentary pharmacology & therapeutics*, 47(3), 421-431.
- Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., ... & Schulten, K. (2005). Scalable molecular dynamics with NAMD. *Journal of Computational Chemistry*, 26(16), 1781-1802. <https://doi.org/10.1002/jcc.20289>
- Rauf, M. A., Zubair, S., & Azhar, A. (2015). Ligand docking and binding site analysis with pymol and autodock/vina. *International Journal of Basic and Applied Sciences*, 4(2), 168.
- Schrödinger, R. (2017-1). Maestro, Schrödinger, LLC, New York, NY, 2017. <https://doi.org/10.1111/jvh.12654>
- Shah, S., Shah, S. R., Chowdhury, A., Mehta, R., Kapoor, D., Duseja, A., Koshy, A., ... & Sarin, S. (2017). Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India. *Journal of Viral Hepatitis*, 24(5), 371-379. <https://doi.org/10.1111/jvh.12654>
- Trott, O., & Olson, A. J. (2010). Auto Dock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. *Journal of Computational Chemistry*, 31(2), 455-461.